Home › Research › Caregiving
Quantification of amyloid PET for future clinical use: a state-of-the-art review
Pemberton HG, Collij LE, Heeman F, Bollack A, Shekari M, Salvadó G, Alves IL, Garcia DV et al.. European journal of nuclear medicine and molecular imaging, 2022-04-07
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer's disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be determined in vivo using positron emission tomography (PET), for which three fluorine-18 labelled radiotracers have been approved for clinical use. In clinical practice, trained readers will categorise scans as either Aβ positive or negative, based on visual inspection. Diagnostic decisions are often based on these reads and patient selection for clinical trials is increasingly guided by amyloid status. However, tracer deposition in the grey matter as a function of amyloid load is an inherently continuous process, which is not sufficiently appreciated through binary cut-offs alone. State-of-the-art methods for amyloid PET quantification can generate tracer-independent measures of Aβ burden. Recent research has shown the ability of these quantitative measures to highlight pathological changes at the earliest stages of the AD continuum and generate more sensitive thresholds, as well as improving diagnostic confidence around established binary cut-offs. With the recent FDA approval of aducanumab and more candidate drugs on the horizon, early identification of amyloid burden using quantitative measures is critical for enrolling appropriate subjects to help establish the optimal window for therapeutic intervention and secondary prevention. In addition, quantitative amyloid measurements are used for treatment response monitoring in clinical trials. In clinical settings, large multi-centre studies have shown that amyloid PET results change both diagnosis and patient management and that quantification can accurately predict rates of cognitive decline. Whether these changes in management reflect an improvement in clinical outcomes is yet to be determined and further validation work is required to establish the utility of quantification for supporting treatment endpoint decisions. In this state-of-the-art review, several tools and measures available for amyloid PET quantification are summarised and discussed. Use of these methods is growing both clinically and in the research domain. Concurrently, there is a duty of care to the wider dementia community to increase visibility and understanding of these methods.
What this study adds
Evidence grade: Low
This is a narrative review. Amyloid PET scans are usually read by eye as simply "positive" or "negative", but this review argues that amyloid builds up continuously and that binary cut-offs alone do not capture it well. It reports that quantitative, tracer-independent measures can flag changes at the earliest stages of Alzheimer's, sharpen diagnostic confidence, and, according to large multi-centre studies it cites, predict rates of cognitive decline.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Pemberton, H. G., Collij, L. E., Heeman, F., Bollack, A., Shekari, M., Salvadó, G., et al. (2022). Quantification of amyloid PET for future clinical use: a state-of-the-art review. European journal of nuclear medicine and molecular imaging. https://doi.org/10.1007/s00259-022-05784-y
Vancouver
Pemberton HG, Collij LE, Heeman F, Bollack A, Shekari M, Salvadó G, et al. Quantification of amyloid PET for future clinical use: a state-of-the-art review. European journal of nuclear medicine and molecular imaging. 2022. doi:10.1007/s00259-022-05784-y. PMID: 35389071.
BibTeX
@article{pemberton2022-35389071,
author = {Pemberton, H. G. and Collij, L. E. and Heeman, F. and Bollack, A. and Shekari, M. and Salvadó, G. and Alves, I. L. and Garcia, D. V. and others},
title = {{Quantification of amyloid PET for future clinical use: a state-of-the-art review}},
journal = {European journal of nuclear medicine and molecular imaging},
year = {2022},
doi = {10.1007/s00259-022-05784-y},
pmid = {35389071},
url = {https://doi.org/10.1007/s00259-022-05784-y}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- The overall load and spatial distribution of brain Aβ can be determined in vivo using positron emission tomography (PET), for which three fluorine-18 labelled radiotracers have been approved for clinical use.
- In clinical settings, large multi-centre studies have shown that amyloid PET results change both diagnosis and patient management and that quantification can accurately predict rates of cognitive decline.
Why it matters
Amyloid PET scans are usually read by eye as simply "positive" or "negative", but this review argues that amyloid builds up continuously and that binary cut-offs alone do not capture it well. It reports that quantitative, tracer-independent measures can flag changes at the earliest stages of Alzheimer's, sharpen diagnostic confidence, and, according to large multi-centre studies it cites, predict rates of cognitive decline. It is a review about diagnosis and choosing who enters trials; it does not test any treatment.
New to this subject? Start with our plain-English guide: Caregiving →
Study details
- Evidence strengthLow
How this study scored 54/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (European journal of nuclear medicine and molecular imaging) |
| Journal's citation record | 2 / 4 | European Journal of Nuclear Medicine and Molecular Imaging: journal h-index 224 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 221 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 36.8 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 5 / 6 | Cited 24.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 25 other studies in this library |
| Still being cited | 3 / 4 | Cited 191 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Gill Farrar: h-index 30 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 14 institution(s) in 5 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35389071) |
| Free to read | 2 / 2 | Free to read |
| Total | 54 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1007/s00259-022-05784-y
- PubMed: 35389071
- Original source →
- Free full text: European Journal of Nuclear Medicine and Molecular Imaging →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 53.
Later studies that cite this one
25 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Caregiving from nearby years
Also tagged “machine”
834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.